187 related articles for article (PubMed ID: 34059744)
1. A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants.
Wiik MU; Evans TJ; Belhadj S; Bolton KA; Dymerska D; Jagmohan-Changur S; Capellá G; Kurzawski G; Wijnen JT; Valle L; Vasen HFA; Lubinski J; Scott RJ; Talseth-Palmer BA
Sci Rep; 2021 May; 11(1):11401. PubMed ID: 34059744
[TBL] [Abstract][Full Text] [Related]
2. Genetic variant in the telomerase gene modifies cancer risk in Lynch syndrome.
Bellido F; Guinó E; Jagmohan-Changur S; Seguí N; Pineda M; Navarro M; Lázaro C; Blanco I; Vasen HF; Moreno V; Capellá G; Wijnen JT; Valle L
Eur J Hum Genet; 2013 May; 21(5):511-6. PubMed ID: 22948024
[TBL] [Abstract][Full Text] [Related]
3. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome.
Gargiulo S; Torrini M; Ollila S; Nasti S; Pastorino L; Cusano R; Bonelli L; Battistuzzi L; Mastracci L; Bruno W; Savarino V; Sciallero S; Borgonovo G; Nyström M; Bianchi-Scarrà G; Mareni C; Ghiorzo P
Fam Cancer; 2009; 8(4):547-53. PubMed ID: 19728162
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
[TBL] [Abstract][Full Text] [Related]
5. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
6. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
[TBL] [Abstract][Full Text] [Related]
7. MTHFR C677T and A1298C polymorphism's effect on risk of colorectal cancer in Lynch syndrome.
Wiik MU; Negline M; Beisvåg V; Clapham M; Holliday E; Dueñas N; Brunet J; Pineda M; Bonifaci N; Aretz S; Klinkhammer H; Spier I; Perne C; Mayr A; Valle L; Lubinski J; Sjursen W; Scott RJ; Talseth-Palmer BA
Sci Rep; 2023 Nov; 13(1):18783. PubMed ID: 37914736
[TBL] [Abstract][Full Text] [Related]
8. A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance-functional analysis reveals the pathogenic one.
Kantelinen J; Hansen TV; Kansikas M; Krogh LN; Korhonen MK; Ollila S; Nyström M; Gerdes AM; Kariola R
Fam Cancer; 2011 Sep; 10(3):515-20. PubMed ID: 21431882
[TBL] [Abstract][Full Text] [Related]
9. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
[TBL] [Abstract][Full Text] [Related]
10. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
11. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
[TBL] [Abstract][Full Text] [Related]
12. TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study.
Kamiza AB; Hsieh LL; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; You JF; Wang WC; Hsiung CA; Yeh CC
PLoS One; 2016; 11(12):e0167354. PubMed ID: 27907203
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome.
Talseth-Palmer BA; Brenne IS; Ashton KA; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; Spigelman A; Lubinski J; Scott RJ
J Med Genet; 2011 Apr; 48(4):279-84. PubMed ID: 21097774
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers.
Talseth-Palmer BA; Wijnen JT; Brenne IS; Jagmohan-Changur S; Barker D; Ashton KA; Tops CM; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; ; Spigelman A; Møller P; Morreau HM; Van Wezel T; Lubinski J; Vasen HF; Scott RJ
Int J Cancer; 2013 Apr; 132(7):1556-64. PubMed ID: 22987364
[TBL] [Abstract][Full Text] [Related]
15. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion.
Lynch HT; Riegert-Johnson DL; Snyder C; Lynch JF; Hagenkord J; Boland CR; Rhees J; Thibodeau SN; Boardman LA; Davies J; Kuiper RP; Hoogerbrugge N; Ligtenberg MJ
Am J Gastroenterol; 2011 Oct; 106(10):1829-36. PubMed ID: 21769135
[TBL] [Abstract][Full Text] [Related]
16. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
[TBL] [Abstract][Full Text] [Related]
17. First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.
Ziada-Bouchaar H; Sifi K; Filali T; Hammada T; Satta D; Abadi N
Fam Cancer; 2017 Jan; 16(1):57-66. PubMed ID: 27468915
[TBL] [Abstract][Full Text] [Related]
18. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
19. The spectrum of Lynch syndrome-associated germ-line mutations in Russia.
Yanus GA; Akhapkina TA; Iyevleva AG; Kornilov AV; Suspitsin EN; Kuligina ES; Ivantsov AO; Aleksakhina SN; Sokolova TN; Sokolenko AP; Togo AV; Imyanitov EN
Eur J Med Genet; 2020 Mar; 63(3):103753. PubMed ID: 31491536
[TBL] [Abstract][Full Text] [Related]
20. MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France.
Vermaut C; Leclerc J; Vasseur F; Wacrenier A; Lovecchio T; Boidin D; Rebergue MH; Cattan S; Manouvrier S; Lejeune S; Buisine MP
Genes Chromosomes Cancer; 2020 Feb; 59(2):111-118. PubMed ID: 31433521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
